Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin Sells 54,244 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 54,244 shares of the company’s stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the sale, the chief accounting officer now directly owns 54,410 shares of the company’s stock, valued at $1,360,250. This represents a 49.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Sandra Calvin also recently made the following trade(s):

• On Monday, February 3rd, Sandra Calvin sold 3,348 shares of Travere Therapeutics stock. The shares were sold at an average price of $20.12, for a total transaction of $67,361.76.
• On Wednesday, January 22nd, Sandra Calvin sold 925 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.94, for a total value of $17,519.50.
• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The stock was sold at an average price of $17.22, for a total value of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.30, for a total value of $221,247.00.

Travere Therapeutics Stock Down 2.3 %

TVTX opened at $23.20 on Thursday. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71. The business has a 50 day moving average price of $19.06 and a 200 day moving average price of $15.95. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $25.29.

Analyst Ratings Changes

Several analysts recently commented on the stock. Piper Sandler raised their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the stock a “neutral” rating in a report on Thursday, November 14th. Barclays lifted their target price on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 1st. Canaccord Genuity Group upped their price target on shares of Travere Therapeutics from $22.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday. Scotiabank lifted their price objective on Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a research report on Wednesday. Finally, Evercore ISI boosted their target price on Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $27.77.

Institutional Trading of Travere Therapeutics

Several large investors have recently modified their holdings of the company. R Squared Ltd bought a new position in Travere Therapeutics in the 4th quarter worth $53,000. CWM LLC increased its stake in shares of Travere Therapeutics by 158.5% in the third quarter. CWM LLC now owns 4,999 shares of the company’s stock worth $70,000 after purchasing an additional 3,065 shares during the period. Quarry LP acquired a new position in shares of Travere Therapeutics during the 3rd quarter worth about $105,000. Aigen Investment Management LP bought a new stake in Travere Therapeutics during the 3rd quarter valued at approximately $170,000. Finally, Victory Capital Management Inc. acquired a new stake in Travere Therapeutics in the 4th quarter valued at approximately $182,000.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.